Novelos Therapeutics intends to price public offering of common stock

Agent Rodman & Renshaw assists; deal finances research and development

By Devika Patel

Knoxville, Tenn., April 9 - Novelos Therapeutics Inc. will price a public sale of its common stock, according to a Form S-1 filed Monday with the Securities and Exchange Commission.

Rodman & Renshaw, LLC is the agent for the deal, which is being conducted on a reasonable, best-efforts basis.

Proceeds will be used for research and development activities and general corporate purposes.

Novelos is a Madison, Wis.-based biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.